FINWIRES · TerminalLIVE
FINWIRES

Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says

By

Wave Life Sciences (WVE) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.

The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.

The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.

Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.

Shares of the company were down 2.6% in Friday trading.

Price: $6.72, Change: $-0.18, Percent Change: -2.61%

Related Articles

Australia

RXO Shares Rise After Stifel Upgrade

RXO (RXO) shares were up over 6% in Friday trading after Stifel upgraded the stock to buy from hold with a price target of $22.Trading volume stood at more than 2.6 million shares, compared with a daily average of about 2.1 million.Price: $18.61, Change: $+1.10, Percent Change: +6.25%

$RXO
Australia

Aveanna Healthcare Shares Rise After Stephens Upgrade

Aveanna Healthcare (AVAH) shares rose 4.1% on Friday after Stephens upgraded the stock to overweight from equalweight and adjusted its price target to $11 per share from $10.Trading volume stood at over 1.9 million shares compared with a daily average of more than 1.3 million.Price: $7.75, Change: $+0.31, Percent Change: +4.17%

$AVAH
Australia

Update: Figma Shares Rise After Q1 Adjusted Net Income, Revenue Beat Estimates

(Updates with recent stock movement in headline and first paragraph.)Figma (FIG) shares were up 14% in afternoon trading on Friday after the company posted Q1 adjusted net income and revenue that surpassed analysts' consensus.The company reported Q1 adjusted net income late Thursday of $0.10 per diluted share, up from $0.03 a year earlier.Analysts polled by FactSet expected $0.06.Revenue for the three months ended March 31 rose to $333.4 million from $228.2 million a year earlier.Analysts surveyed by FactSet expected $316 million.The company expects fiscal Q2 revenue of $348 million to $350 million. Analysts expect $329.5 million.The company expects full-year 2026 revenue of $1.42 billion to $1.43 billion, compared with $1.366 billion to $1.374 billion previously. Analysts expect $1.37 billion.Price: $23.21, Change: $+2.97, Percent Change: +14.65%

$FIG